The timing of such NRF2 responses may be especially relevant for fractionated IR treatments in the clinic and for the induction of IR-induced tumor immunity, which is being considered as a means to expand the use of immune checkpoint inhibitors in cancer treatment [3,103,104]. Here, NFE2L2 is linked to cancer.